Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

Rhea-AI Summary

Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 p.m. ET. This leading clinical-stage genome editing company focuses on developing CRISPR-based therapeutics. Interested parties can access a live audio webcast of the presentation on Intellia’s website, with a replay available for two weeks afterward.

Intellia is advancing innovative therapies through in vivo and ex vivo CRISPR programs, demonstrating its leadership in genetic medicine.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.

A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of the Investors & Media section on the company’s website at www.intelliatx.com. A replay of the audio webcast will be available on Intellia’s website for at least two weeks following the presentation.

About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com

Lina Li
Director, Investor Relations
+1-857-706-1612
lina.li@intelliatx.com

FAQ

When is Intellia Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Intellia Therapeutics will present on January 12, 2022, at 2:15 p.m. ET.

How can I access the live webcast of Intellia's presentation?

The live audio webcast can be accessed on Intellia's Investors & Media page on their website.

What focus areas does Intellia Therapeutics specialize in?

Intellia specializes in genome editing and developing curative therapeutics using CRISPR-based technologies.

What programs is Intellia pursuing in genome editing?

Intellia is pursuing in vivo and ex vivo CRISPR programs to develop therapies for genetic diseases and certain cancers.

Where can I find more information about Intellia Therapeutics?

More information is available on Intellia's website, including details on presentations and their CRISPR-based technologies.